by Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates with a high fatality rate of around 50%. The disease was first detected in 1976 near the Ebola River in the Democratic Republic of the Congo. Major symptoms of Ebola include fever, sore throat, muscular pain, headaches and severe lethargy. This is followed by vomiting, diarrhea and rash in some patients. Subsequently, patients may bleed internally as well as externally. Currently, there is no licensed vaccine for the prevention of Ebola virus disease approved by the World Health Organization, although multiple candidate vaccines are currently at different stages of development and testing. The global ebola vaccine market is dominated by pharmaceutical giants that are focusing on research and development activities to introduce effective vaccines against the Ebola virus infection.
The global Ebola Vaccine Market is estimated to be valued at Us$ 5.83 Bn in 2024 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing governmental initiatives for ebola prevention is expected to drive the ebola vaccine market growth over the forecast period. Governments across various countries are collaborating with WHO and other non-profit organizations to spread awareness related to ebola and develop effective preventive measures. For instance, the U.S. Centers for Disease Control and Prevention (CDC) works closely with Ministries of Health in African countries to strengthen their capacity to prevent, rapidly detect, and effectively respond to outbreaks. Additionally, increasing rate of ebola outbreaks worldwide is also fueling the need for a standardized ebola vaccine. As per CDC statistics, since 1976, there have been over 25 known outbreaks of Ebola virus in Africa with the 2014 West African epidemic being the largest and most complex ebola outbreak till date. Therefore, growing threats of ebola epidemics are projected to boost the adoption of ebola vaccines.
Segment Analysis
The global Ebola vaccine market is segmented on the basis of type of vaccine candidate such as Inactivated Vaccine, Live Attenuated Vaccine, Non-Replicating Vaccine, and Virus-Like Particle Vaccine. Among these, the inactivated vaccine segment dominates the market and holds more than 30% share owing to wide adoption rate of inactivated vaccines which induces both humoral and cell-mediated immunity. The non-replicating vaccine segment is expected to witness the fastest growth during the forecast period due to ongoing research and development activities and robust developmental pipeline of non-replicating vaccine candidates.
PEST Analysis
Political: Emergence of various non-profit organizations and international bodies like WHO to accelerate the research and development activities towards development of effective vaccine against Ebola virus will boost market growth.
Economic: Rising research funding from both private and public bodies in endemic regions like Africa will drive the demand.
Social: Growing health issues associated with Ebola epidemics have enhanced the social awareness related to prevention and spread of Ebola virus, thereby fuelling the market.
Technological: Advancements in viral vector technologies, nanoparticles, and genetic engineering approaches are facilitating the development of effective vaccine candidates.
Key Takeaways
The Global Ebola Vaccine Market Demand is expected to witness high growth at a CAGR of around 9.4% during the forecast period of 2023-2030.
Regional analysis indicates that Africa holds a major share of over 40% owing to recurring epidemics in countries like DR Congo and ongoing vaccination efforts in high risk regions.
Key players operating in the Ebola vaccine market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. Key players are focusing on strategic collaborations to accelerate the clinical development and commercialization of new vaccine candidates. Moreover, major players are involved in expanding their regional presence across high burden countries in Africa through partnerships with local authorities.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
